He Yan, Zhao Zhihao, Wang Ying, Chai Jiamin, He Jialing, Wang Jingjing, He Ling, Guan Hui, Wei Zhigong, Liu Zheran, Mu Xiaoli, Peng Xingchen
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China.
Head Neck. 2020 Aug;42(8):2067-2076. doi: 10.1002/hed.26141. Epub 2020 Mar 23.
Induction chemotherapy followed by concurrent chemoradiotherapy is one of the standards of care for patients with nasopharyngeal carcinoma, but the optimal number of induction cycles is unclear. Here we compared survival data from patients treated with 2 to 4 cycles.
Patients with nasopharyngeal carcinoma at West China Hospital of Sichuan University between January 2009 and December 2015 were retrospectively analyzed.
Six hundred and seventy three patients met eligibility criteria. After a median follow-up of 53 months (interquartile range, 38-74), there was no difference between 2 and 3 cycles in overall survival (88.14% vs 91.24%). But four cycles were associated with worse overall survival (79.12%) and higher incidence of treatment-related toxicities. Multivariate analysis showed that the number of induction cycles and lymph node classification were prognostic factors.
Two and three cycles of induction chemotherapy are associated with similar survival, while four cycles reduce survival and increase treatment-related toxicity in endemic regions.
诱导化疗后序贯同步放化疗是鼻咽癌患者的标准治疗方案之一，但最佳诱导周期数尚不清楚。在此，我们比较了接受2至4个周期治疗的患者的生存数据。
对2009年1月至2015年12月期间在四川大学华西医院接受治疗的鼻咽癌患者进行回顾性分析。
673例患者符合入选标准。中位随访53个月（四分位间距，38 - 74个月）后，2个周期和3个周期的总生存率无差异（88.14%对91.24%）。但4个周期与较差的总生存率（79.12%）及较高的治疗相关毒性发生率相关。多因素分析显示，诱导周期数和淋巴结分类是预后因素。
在流行地区，2个周期和3个周期的诱导化疗生存率相似，而4个周期会降低生存率并增加治疗相关毒性。
